Tyra Biosciences, Inc.
$34.37
▲
3.47%
2026-04-21 09:58:01
tyra.bio
NMS: TYRA
Explore Tyra Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.92 B
Current Price
$34.37
52W High / Low
$40.65 / $7.8
Stock P/E
—
Book Value
$4.83
Dividend Yield
—
ROCE
-50.19%
ROE
-39.83%
Face Value
—
EPS
$-2.01
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
87
Beta
0.96
Debt / Equity
2.24
Current Ratio
14.67
Quick Ratio
14.67
Forward P/E
-13.77
Price / Sales
—
Enterprise Value
$1.65 B
EV / EBITDA
-12.47
EV / Revenue
—
Rating
Strong Buy
Target Price
$50.96
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Metagenomi Therapeutics, Inc. | $1.53 | — | $55.68 M | — | -48.45% | -44.66% | $3.95 / $1.25 | $4.22 |
| 2. | Aligos Therapeutics, Inc. | $6.51 | — | $41.33 M | — | -130.74% | -1.97% | $13.69 / $4.2 | $8.67 |
| 3. | Aktis Oncology, Inc. | $20.83 | — | $1.08 B | — | -31.96% | -29.45% | $29.16 / $14.72 | $-159.68 |
| 4. | CNS Pharmaceuticals, Inc. | $2.69 | — | $2.06 M | — | -241.26% | -2.96% | $34.8 / $2.06 | $17.25 |
| 5. | Evommune, Inc. | $27.97 | — | $988.7 M | — | -39.16% | -54.42% | $33.2 / $13.88 | $6.52 |
| 6. | Dianthus Therapeutics, Inc. | $91.92 | — | $5 B | — | -35.57% | -38.38% | $96.5 / $16.64 | $11.41 |
| 7. | Atrium Therapeutics, Inc. | $14.3 | — | $239.4 M | — | -32.47% | -104.92% | $73.06 / $11.95 | $-4.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -36.52 M | -32.94 M | -31.45 M | -31.85 M | -29.74 M |
| Net Profit | -33.83 M | -29.87 M | -28.1 M | -28.15 M | -25.57 M |
| EPS in Rs | -0.63 | -0.55 | -0.52 | -0.52 | -0.47 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -132.76 M | -104.18 M | -79.94 M | -58.93 M |
| Net Profit | -119.95 M | -86.48 M | -69.13 M | -55.33 M |
| EPS in Rs | -2.23 | -1.61 | -1.28 | -1.03 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 282.61 M | 363.56 M | 225.86 M | 266.18 M |
| Total Liabilities | 23.43 M | 20.41 M | 21.59 M | 8.35 M |
| Equity | 259.18 M | 343.15 M | 204.26 M | 257.83 M |
| Current Assets | 265.45 M | 347.46 M | 211.67 M | 257.29 M |
| Current Liabilities | 18.09 M | 14.59 M | 15.33 M | 5.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -95.14 M | -69.77 M | -50.14 M | -50.28 M |
| Investing CF | 72.46 M | -98.4 M | -144.6 M | -0.56 M |
| Financing CF | 8.1 M | 202.14 M | 1.54 M | 0.63 M |
| Free CF | -95.28 M | -70.44 M | -50.91 M | -50.84 M |
| Capex | -0.14 M | -0.66 M | -0.77 M | -0.56 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -25.09% | -24.96% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.